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Summary 
Duchenne muscular dystrophy (DMD) is characterized by clinical weakness and progressive necrosis 
of striated muscle as a consequence of dystrophin deficiency.  While all skeletal muscle groups 
are thought to be affected, enigmatically, the extraocular muscles (EOM) appear clinically unaffected. 
Here we show that dystrophin deficiency does not result in myonecrosis or pathologically elevated 
levels of intracellular calcium ([Ca2+]i) in EOM.  At variance with a previous report, we find 
no evidence for dystrophin-related protein/utrophin up-regulation in EOM. In vitro experiments 
demonstrate that extraocular muscles are inherently more resistant to necrosis caused by phar- 
macologically elevated [Ca2+]i levels when compared with pectoral musculature. We believe that 
EOM are spared in DMD because of their intrinsic ability to maintain calcium homeostasis better 
than other striated muscle groups.  Our results indicate that modulating levels of [Ca2+]i in 
muscle may be of potential therapeutic use in DMD. 
D 
uchenne/Becker muscular dystrophy (DMD) 1 is one of 
the most common inherited neuromuscular diseases. 
The disease is of particular importance because of its relent- 
less course of progression and debilitating nature, for which 
no effective therapies currently exist (1). Over the last de- 
cade, it has emerged that the etiology of the disease is a pri- 
mary defect in the DMD gene that leads to quantitative and/or 
qualitative abnormalities in the expression of dystrophin, the 
protein product of this gene (2, 3). DMD is clinically charac- 
terized by slow but progressive muscle weakness due to necrosis 
of skeletal muscle fibers. While all muscle groups are thought 
to be affected by the absence of dystrophin, enigmatically, 
the extraocular muscles (EOM) remain clinically unaffected 
during the course of the disease (1, 4). This observation has 
led to a great deal of interest in understanding the compensa- 
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tory factor(s) or mechanism(s) that allow EOM to escape the 
deleterious consequences of dystrophin deficiency. 
Dystrophin belongs to the spectrin superfamily of proteins, 
the members of which share overall structural similarities (5). 
These proteins contain an actin-binding region at the amino 
terminus and a rodlike central domain consisting of tandemly 
repeated, spectrinlike amino acid motifs. Functionally, these 
proteins share properties such as morphology, calcium-binding 
potential, and tightly regulated cellular and subcellular dis- 
tribution (5, 6). The dystrophin class of the spectrin superfa- 
mily currently consists of chromosome X-encoded dystro- 
phin,  chromosome  6-encoded  dystrophin-related  protein 
(DRP)/utrophin,  and, more distantly, the 87-kD chromo- 
some 18-encoded dystrophinlike protein (5, 7-10). The pro- 
teins share significant sequence similarity, size, evolutionary 
conservation, abundance, and some aspects of subcellular dis- 
tribution in normal skeletal muscle, such as enrichment at 
neuromuscular and myotendinousjunctions (2, 5, 7, 8, 11-14). 
Furthermore, dystrophin and DKP copurify with a complex 
of proteins known as the dystrophin-associated glycoprotein 
complex, which contributes to anchoring and localizing both 
proteins to the sarcolemma (15,  16). Dystrophin and DKP 
are critical components of the chain of cytoskeletal elements 
that links internal cellular structures, e.g., actin bundles, to 
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18). Dystrophin and its relatives are thought to help in the 
genesis and maintenance of subcellular membrane specializa- 
tions and to protect the sarcolemma from structural damage 
that occurs during multiple contraction-relaxation cycles in 
the skeletal muscle leading to myonecrosis (17,  19). 
Members of the dystrophin family have been strongly con- 
served over evolution. Consequently, dystrophin deficiency 
due to mutations in the DMD gene has been described and 
characterized in a number of animal species, including mice 
(mdx), dogs (cxmd),  and cats, all of which are considered 
useful animal models for the disease (17, 20).  These animal 
models share the same biochemical defect as DMD (i.e., se- 
vere dystrophin deficiency), albeit with differing functional 
consequences. The mdx mouse used in most studies (including 
this one) has a mutation at nucleotide position 3185 resulting 
in translation termination within the amino-terminal third 
of the molecule (21). Recently, additional allelic forms of the 
mdx mouse have been generated (mdx z-4cv) with mutations 
in the 3' end of the murine cDNA (22).  Interestingly, while 
the mdx mouse demonstrates loci of myonecrosis in skeletal 
muscle, cardiomyopathy, and elevated creatine kinase levels 
similar to human DMD patients throughout most of its life, 
it does not exhibit extensive muscle fibrosis or clinical weak- 
ness as seen in humans, except for some muscle groups such 
as the diaphragm (23,  24).  The feline model of DMD has 
a deletion in the muscle promoter region of the gene and 
shares features such as myonecrosis, weakness, muscle hyper- 
trophy, and extensive fibrosis with the human disease (25). 
Interestingly, dystrophin-deficient cats suffer from esophageal 
obstruction as a consequence of muscle hypertrophy, a fea- 
ture not seen in human patients (26). The dog model of DMD 
is remarkably similar to human muscular dystrophy, both in 
terms of histopathology and clinical progression due to skeletal 
muscle necrosis and cardiomyopathy (27).  The cxmd muta- 
tion on a golden retriever background (used in this study) 
is known to be due to a messenger RNA processing error 
occurring because of a mutation in the consensus splice ac- 
ceptor site in exon 6 of the dystrophin molecule (28).  Al- 
though these animal models have species-specific differences 
in their clinical courses, they nevertheless occupy an impor- 
tant place in understanding human disease and serve as excel- 
lent models for studies concerning dystrophin deficiency. 
Clinicians have long suggested that EOM dysfunction is 
not a cardinal feature of the otherwise widespread muscle 
weakness in DMD.  Indeed, a recent clinical study demon- 
strated that saccadic eye movements in DMD patients were 
indistinguishable from those of controls (4).  However, de- 
spite an extensive review of literature, we were unable to find 
any histological analyses of EOM in confirmed DMD cases. 
Indeed, the enigmatic clinical sparing of EOM along with 
the lack of histological information about EOM in DMD 
prompted this study. As a muscle group, EOM exhibit marked 
differences in their developmental, morphological, and phys- 
iological properties when compared with other skeletal muscle 
groups. These differences have been attributed to the unique 
demands made on EOM in providing the correct combina- 
tion of smooth and saccadic eye movements to impart an 
efficient usage of foveal vision in mammals. These differences 
include, but are not restricted to, a unique, weU-demarcated 
fiber-type layering of myofibers (29); presence of motor units 
capable of firing at 'o600 Hz compared with ~200 Hz in 
the extremity, and "hyper-fast" twitch fibers capable of the 
fastest known contractile responses (30). Additionally, EOM 
exhibit "en-grappe" type of neuromuscular  junctions and are 
the only known example of multiple innervation in mam- 
malian species (31). These features make EOM dysfunction 
an early and sometimes the sole presenting feature in certain 
diseases,  e.g.,  myasthenia gravis,  congenital fibrosis  of the 
EOM, and some mitochondrial diseases. Conversely, clinical 
sparing of ocular function has been reported in DMD and 
motor neuron disease, where pathology is evident in a wide 
variety of non-EOM skeletal  muscle groups (1,  4,  32). 
It has been argued on theoretical grounds that, in DMD, 
the EOM may escape damage because they express high levels 
of a homologue/isoform of dystrophin, i.e., dystrophin-related 
protein(s), which can functionally compensate for the genetic 
lesion (33). Alternatively, it has been proposed that the unique 
anatomical and physiological properties of EOM may sufficiendy 
explain the minimal morbidity of this muscle group in DMD 
(4).  While these issues have not been studied in DMD pa- 
tients,  the first hypothesis was supported by a study that 
demonstrated that dystrophin-deficient mdx mice expressed 
greater amounts of DRP in skeletal,  cardiac, and EOM and 
correlated the DRP overexpression with the lack of clinical 
weakness  in  these  muscle  groups  (16). However,  it  is 
noteworthy that dystrophin and DRP differ in a number of 
properties,  such as the pattern of their tissue distribution, 
developmental expression, and subcellular localization in both 
muscle and brain (7, 8, 12, 13, 34-39). To address the ques- 
tion of whether it is the overexpression of DRP or other 
physiological  differences  that  compensate  for  dystrophin 
deficiency in the EOM of DMD patients, we used a com- 
bined approach of histological, immunohistochemical, and 
pharmacological methods in human, murine, and canine EOM 
from normal and dystrophin-deficient individuals. 
Materials  and Methods 
Immunoblotting.  The methods used for immunoblotting have 
been previously described (12). Briefly, weighed aliquots of tissue 
were solubilized in sample buffer and boiled. Protein concentra- 
tions were measured using a colorimetric assay, and samples nor- 
malized by dilution to achieve  uniform loading of protein. Aliquots 
were fractionated on a 3.5-12.5% gradient SDS-polyacrylamide  gel. 
Subsequently, proteins were electrotransferred onto nitrocellulose 
filters. Filters were stained with Ponceau S solution, which, to- 
gether with the transfer of prestained protein molecular weight 
standards, served to control for the efficiency of transfer. Filters 
were incubated with the affinity-purified anti-DRP (rabbit) anti- 
body. Antibody complexes  were detected using chemiluminescence 
or alkaline  phosphatase  staining. Bands were quantified  using Image- 
quant software (Molecular Dynamics, Inc., Sunnyvale, CA). 
Immunohistochemistry  and Histopathology.  Immunohistochemistry 
was performed using previously  described  methods (12). Tissue from 
C57 B10 mdx mice, cxmd  dogs, and controls as well as from clini- 
cally and biochemically confirmed DMD patients was obtained on 
468  Extraocular  Muscles in Duchenne Muscular Dystrophy Figure 1.  H&E staining of DMD muscle. Paraf~n-embedded  sections from 14-yr-old DMD autopsy case were prepared from (A) EOM (lateral rectus), 
and (B) limb muscle (quadriceps).  Classical pathological changes of DMD,  including fiber hypertrophy, fiber size variation, fiber splitting, central 
nucleation, and fatty change are clearly visible in limb muscle (B); however, the EOM from the same patient (.4) are normal in appearance. Bar, 25 
/xm for A  and 50/~m for/g 
469  Khurana et al. Figure 2.  Dystrophin immunofluorescence  of control human, DMD, mdx, and cxmd  EOM. Dystrophin antibodies were used to label frozen sections 
of EOM obtained from (A) human control, (B) human DMD patient, (C) cxmd dog, and (D) mdx mouse. While normal sarcolemmal labeling using 
dystrophin antibodies is visible in control EOM (A), there is no detectable labeling in dystrophin deficient EOM from various species (B D). Bar, 25/zm. 
autopsy, and control EOM tissue was obtained as an operation speci- 
men. Tissue was flash frozen, and 5-10/zm cryosections were cut 
and lifted onto electrostaticaUy charged slides. Sections were fixed 
with cold methanol and washed with PBS before being labeled with 
dystrophin antibody (d6-10) in PBS with 10% calf serum at a dilu- 
tion of 1:2,000 for 1 h at room temperature (35).  After washing 
in PBS, sections  were incubated with Cy3 anti-rabbit IgG anti- 
body {Jackson Immunological Laboratories, Bethesda, MD) for 1 h. 
Washed sections  were mounted in Aqua-mount (Lerner  Labora- 
tories, Pittsburgh, PA). Sections were examined using a microscope 
(Axiophot; Carl Zeiss, Inc., Thornwood, NY) equipped with epi- 
fluorescence optics. Hematoxylin and eosin (H&E) and alizarin red 
staining were performed as per standard histological protocols. 
Ex Vivo Calcium Loading.  Pectoral,  limb,  and EOM were dis- 
sected within I h postmortem from outbred male hounds weighing 
between 20 and 30 kg, used for studies  of acute cardiac dysfunc- 
tion at the Cardiology Research  Unit (Johns  Hopkins Hospital, 
Baltimore,  MD).  Small segments measuring 1  x  0.2  x  0.2 cm 
of muscle were placed on HBSS-beaded  dental wax pallets and in- 
jected with HBSS,  calcium ionophore A-23187  (25-100/~g/ml), 
or cyclopiazonic acid (CPA; 50/zM).  50/zl of these reagents  was 
delivered by microsydnge (Hamilton Co., Reno, NV) through a 
30-gauge needle centrally placed into each muscle segment. After 
incubation at 37~  for 30-60 min at 100% humidity, the muscle 
segments were washed in HBSS and submerged in 4% formalin, 
Figure 3.  Immunoblot analysis of DRP content in DMD, mdx, and 
cxmd muscles. Aliquots of EOM and limb muscle from DMD, mdx, and 
cxmd were solubilized  in protein sample  buffer  and quantitated, and equiva- 
lent amounts were separated by electrophoresis, immunoblotted  with DRP 
antibodies, and quantified by densitometric  analysis. An equivalent amount 
of DRP was detected in each set of lanes. Uniformity of loading and 
efficiency  of  transfer were  based on Coomassie  staining  of  posttransfer myosin 
as well as Ponceau S staining of the filter (not shown). 
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muscle. 10-/am  cryostat  sections  were  cut from  EOM 
from a DMD patient and stained  with the calcium- 
sensitive  dye, alizarin red. The dye failed  to stain any 
fibers  in the EOM from this patient. The inset shows 
a positive control of alizarin red staining in limb 
muscle from a different DMD patient. Bar, 30/am 
for the full figure, 50/am for the inset. 
pH 7.2. After fixation, the terminal 1 mm was excised from each 
fragment by blue blades (The Gillette Corp., Boston, MA). Rou- 
tine histologic examination of three cross-sections of each muscle 
segment was performed. Over 50 samples from each muscle group 
from  15 dogs were analyzed by this procedure. 
Results and Discussion 
To explore reports of clinical  sparing of EOM in dystro- 
phin deficiency,  we performed histopathological  analysis  of 
EOM and limb muscles obtained from dystrophin-deficient 
humans  (DMD), dogs (cxmd), and mice (mdx). Tissue sec- 
tions stained using H&E clearly revealed that the EOM from 
dystrophin-deficient  tissue were remarkably  healthy in  ap- 
pearance and indistinguishable from the previously reported 
appearance of EOM of healthy individuals (29). Specifically, 
DMD EOM lacked the cardinal pathological manifestations 
ofdystrophin deficiency such as hypertrophy, fiber size varia- 
tion, fiber splitting,  central  nucleation,  fatty degeneration, 
and fibrotic scarring.  In  agreement  with previous reports, 
these features were readily visible in limb musculature  ob- 
tained from the same DMD individual as shown in Fig.  1. 
Similar  histological  studies  in  two additional  DMD  cases, 
one cxmd  dog and two mdx mice, revealed sparing of the EOM 
despite dystrophin  deficiency (data not  shown). 
Since EOM are known to exhibit certain physiological differ- 
ences (e.g.,  innervation  patterns,  EOM-specific transcripts) 
when compared with other  skeletal  muscle,  it was impor- 
tant  to determine if the mechanism  of histological  sparing 
of EOM was associated with a lack and/or novel pattern of 
dystrophin expression in EOM when compared with limb 
musculature.  Immunofluorescence analysis  using the d6-10 
dystrophin  antibody revealed sarcolemmal  labeling in  con- 
trol EOM in a manner indistinguishable from that previously 
noted in limb musculature, with strongly positive myofibers 
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patients, cxmcl dogs, or mdx mice did not express detectable 
levels of dystrophin using this antibody (Fig. 2). Neither con- 
trol nor DMD EOM expressed detectable levels of the non- 
muscle, alternative dystrophin transcripts Dp 71 or Dp 116 
as determined using the carboxy-terminal specific dystrophin 
antibody dll  (40--42) (data not shown). Given the normal 
distribution of dystrophin labeling in EOM and the absence 
of labeling in EOM from DMD patients, cxmd dogs, and 
mdx mice, it is unlikely that the clinical sparing of this muscle 
group occurs because of EOM-specific differences in the quan- 
tity, nature,  and distribution of dystrophin expression. 
Despite the absence of any form of dystrophin in DMD 
EOM, it is possible that they could be spared of necrosis be- 
cause of overexpression of DRP, which may functionally sub- 
stitute for dystrophin in this muscle group. To test this hy- 
pothesis, tissue samples from EOM and limb muscle from 
DMD patients, cxmd dogs, and radx mice were quantitated 
and immunoblotted using afhnity-purified DIKP antibodies 
that we had previously used to identify DRP (8). Fig. 3 demon- 
strates that similar levels of DRP are expressed in all these 
tissues, with no evidence ofDRP overexpression as described 
by Matsumura et al. (16) being found in mdx EOM samples. 
To confirm these results we performed similar experiments 
on an additional case of DMD, cxmcI, and mdx EOM and 
limb muscle; however, contrary to the findings of Matsumura 
et al., we obtained similar results in each instance. To elimi- 
nate observer bias,  one set of experiments was performed 
"blind"  i.e.,  without  prior  knowledge of the identity of 
samples (data not shown). Thus,  despite careful, objective 
analysis, we have obtained no evidence for the D1KP overex- 
pression in mdx EOM reported by Matsumura et al. In fact, 
our studies clearly demonstrate that DRP overexpression does 
not occur in DMD, cxmd, or mdx EOM. It is possible that 
the differences in DRP levels reported by these authors could 
be due to differences in antibody specificity, experimental error, 
or observer bias,  since these issues were not controlled for 
by Matsumura et al. It should also be pointed out that the 
Matsumura study discussed here also  reported DIKP over- 
expression in mdx limb muscle, a finding for which conflicting 
reports currently exist in the literature (8, 14, 37). Given the 
number of experiments we performed and the analysis of EOM 
from three different species,  we conclude that DRP over- 
expression  is  not  responsible  for  the  relative  sparing  of 
dystrophin-deficient EOM in either mdx, cxmcl, or human 
DMD  cases. 
Since DRP overexpression was ruled out as a mechanism 
for sparing EOM in dystrophin deficiency, we addressed other 
physiological factors/processes in muscle germane to the pro- 
cess of myonecrosis. One such candidate process was main- 
tenance of calcium homeostasis, which has long been sug- 
gested to play a pivotal role in DMD muscle pathophysiology 
(43).  An elevated level of total intracellular calcium [Ca2+]i 
and the subsequent activation of calcium-activated proteases 
are well-characterized steps  in the final common pathway 
leading to muscle necrosis in dystrophin deficiency. Indeed, 
in DMD, •5%  of skeletal muscle fibers stain positively with 
the calcium sensitive dye alizarin red (44),  indicating that 
these fibers contain pathologically elevated levels of intracel- 
lular calcium [Ca2+]i. To address the role [Ca2+]i plays in the 
Iack of pathogenesis of dystrophin-deficient EOM, we stained 
these EOM with alizarin red to identify what fibers, if any, 
contained  elevated  levels  of  [Ca2+]i. Remarkably,  the 
calcium-sensitive dye failed to stain any fibers in the EOM 
(the rectus) from a DMD patient (Fig. 4). Additionally, we 
tested sections cut from other EOM groups (the obliques) 
from this patient,  from an additional DMD patient, from 
two cxmd dogs, and from three mdx mice, none of which 
showed positive staining with this dye (data not shown). The 
lack of fibers containing pathologically elevated,  millimolar 
levels of [Ca2+]i in dystrophin-deficient EOM is indicative 
of the ability of this muscle group to continue to maintain 
calcium homeostasis despite the lack of dystrophin. 
To further analyze the calcium homeostatic mechanisms 
of EOM, we treated freshly dissected dog EOM and pectoral 
muscles with the calcium ionophore A23187. This drug causes 
widespread necrotic damage in the myofiber because of a 
marked elevation of [Ca2+]i. Interestingly, the pathological 
lesions caused by this reagent are remarkably similar to the 
lesions seen in DMD patients in vivo, as demonstrated by 
Pestronk et al.  (45).  Consistent with previous reports, cal- 
cium  ionophore-treated  pectoral  muscles  were  markedly 
necrotic, and the lesions resembled the pathology usually seen 
in dystrophin-deficient skeletal muscle (Fig. 5). Surprisingly, 
administration of the same reagent in parallel did not cause 
any detectable muscle damage or necrosis in EOM (Fig.  5). 
To validate these results, we used another pharmacological 
agent, CPA, to perturb the calcium homeostatic mechanism 
in these muscles. CPA blocks the reuptake of [Ca2+]i by the 
sarcoplasmic reticulum and hence causes an increase in the 
levels of [Ca2+]i by using a pathway independent of A23187 
(46).  As shown in Fig.  5,  CPA alone and in combination 
with A 23187 caused the expected necrotic damage in pec- 
toral muscle but was unable to cause detectable muscle damage 
or necrosis in EOM taken from the same dog. These experi- 
ments are suggestive of the superior ability of EOM to main- 
tain calcium homeostasis when challenged with elevated in- 
tracellular calcium levels; however, the precise mechanism by 
which they do so remains unclear. A detailed analysis of the 
presence/absence and the amounts of calcium-binding pro- 
teins, mitochondria, and calcium-activated proteases (e.g., cal- 
pain), as well as quantification of the amount of [Ca2+]i in 
these muscle groups during pharmacological manipulation 
and in disease states using calcium-sensitive dyes (e.g., fura- 
2),  are some obvious future experiments in this regard. 
In conclusion, we find that dystrophin-deficient EOM are 
spared the widespread muscle necrosis that affects other stri- 
ated muscle groups (Fig.  1). At variance with a previous re- 
port, we did not find any evidence for elevated DRP levels 
in dystrophin-deficient EOM (Fig.  3). Based on physiolog- 
ical and pharmacological experiments described here, we sug- 
gest that dystrophin-deficient EOM are spared the patholog- 
ical consequences of dystrophin deficiency,  at least in part, 
because the inherent ability of these muscle groups to main- 
tain calcium homeostasis is better than that of other muscle 
groups (e.g., pectoral or limb muscle) (Figs. 4 and 5). The 
472  Extraocular  Muscles in Duchenne  Muscular Dystrophy Figure 5.  Ex vivo calcium loading in dog EOM and pectoral muscle.  Canine pectoral muscles (A-C) or EOM (D-F) were rapidly dissected and 
incubated with A 23187 (A, D), CPA (/3, E), or a combination of these drugs (C, F) for a period of 30 min. Specimens were embedded in paraffin 
and processed for routine histology. While pathological changes are visible in pectoral muscles treated with these drugs (A-C), the EOM (D-F) are 
resistant to pharmacological elevation  of intracellular calcium levels. Original magnification: 360,  reduced  by the journal 26%. 
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nisms play in compensating for the lack of dystrophin (Figs. 
4 and 5) may yield important clues for developing potential 
therapeutic strategies for Duchenne muscular dystrophy. It 
may be useful to reevaluate  previous drug trials using cal- 
cium channel blockers that had been undertaken in advanced 
cases of DMD (47) in light of our finding that efficient cal- 
cium homeostasis allows EOM to escape the onset of  necrosis 
rather than delaying the progression of necrosis. The ex vivo 
calcium-loading paradigm described in this study may be useful 
in identifying drugs that prevent myonecrosis and in evalu- 
ating these drugs in the prevention of clinico-pathological 
changes in well-studied animal models and preparations,  such 
as dystrophin-deficient dogs, cats, and/or the diaphragm of 
mdx mice (24,  26, 27). 
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